Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3141-3160 of 3,900 trials

Lymphoma Treatment: Loncastuximab Tesirine

We are studying a new treatment for patients with relapsed or refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma after CAR T-cell therapy. The goal is to see if it improves response rates and survival outcomes.

B-cell Non-Hodgkin's Lymphoma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Psilocybin for Chemotherapy-Induced Pain Relief

We are exploring whether psilocybin can help reduce chronic pain for patients recovering from chemotherapy. The goal is to see if it improves daily activities affected by pain.

Chemotherapy-Induced Peripheral Neuropathy3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyOncologyOtolaryngology

ALS and TIA: Hyperpolarized Pyruvate MRI Study

We are testing a new MRI method to see if it can help identify metabolic problems in patients with Amyotrophic Lateral Sclerosis and Transient Ischemic Attack. This may improve our understanding of these conditions.

Amyotrophic Lateral Sclerosis (ALS)Transient Ischemic Attack (TIA)>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementNeurology

ORE-001 for Underweight Elderly Individuals

We are studying whether ORE-001, an oral medication, can help underweight elderly people increase their food intake and improve their health. The trial compares its effects to a placebo to assess safety and overall well-being.

Underweight3-6 monthsEfficacy phase (II)≤5 visitsStandard MedicinesEndocrinologyGastroenterologyInternal Medicine

Delayed Sleep-Wake Phase Disorder: Tasimelteon Study

We are investigating whether tasimelteon can help people with Delayed Sleep-Wake Phase Disorder fall asleep faster and improve their overall sleep quality compared to a placebo.

Delayed Sleep-Wake Phase Disorder≤3 monthsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteNeurologyPsychiatry

Monalizumab for Acute Myeloid Leukemia and Myelodysplastic Syndrome

We are studying the safety and effectiveness of Monalizumab in patients with acute myeloid leukemia or myelodysplastic syndrome receiving a stem cell transplant. This trial aims to understand its impact on recovery and survival.

Acute Myeloid Leukemia1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesHematologyOncology

HER2-Expressing Ovarian Cancer: Trastuzumab Deruxtecan with Bevacizumab

We are studying a new combination treatment for patients with HER2-expressing ovarian cancer to see if it works better than standard therapy. The trial will assess safety and how well the treatments help manage the disease.

Ovarian Cancer>2 yearsConfirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Systemic Sclerosis: Nintedanib and Tocilizumab Study

We are testing a combination of nintedanib and tocilizumab for patients with systemic sclerosis and interstitial lung disease. The goal is to see if this new treatment is more effective than standard therapies.

Systemic SclerosisSystemic Sclerosis with Interstitial Lung Disease1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPulmonologyRheumatology

Crohn's Disease: SAR442970 Study

We are investigating the effects of a new medication, SAR442970, on adults with moderate to severe Crohn's disease. The study aims to see if it helps improve symptoms and overall health compared to a placebo.

Crohn's Disease1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

EPI/HIS Trial: Exploring New Treatment Options

We are investigating a new approach for managing health conditions. This trial aims to understand its effects on patient outcomes.

Healthy Participants>2 yearsSafety phase (I)Internal Medicine

Advanced Non-Small Cell Lung Cancer: MaaT033 and Cemiplimab

We are studying a new treatment combining fecal microbiotherapy with Cemiplimab for patients with advanced NSCLC who have not responded to previous therapies. This trial aims to see if this combination can improve disease control and overall health compared to standard treatments.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Citalopram for Reflux Hypersensitivity and Functional Heartburn

We are studying whether adding citalopram to existing treatments helps patients with reflux hypersensitivity or functional heartburn who still have symptoms. This trial aims to improve symptom relief for those not fully responding to current therapies.

Gastroesophageal Reflux Disease3-6 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPsychiatry

Cancer Treatment: NEXTGEN-TIL-ACT Study

We are assessing a new therapy using tumor-infiltrating lymphocytes for cancer patients. The goal is to evaluate how safe and tolerable this treatment is.

Malignant Solid Tumor>2 yearsSafety phase (I)Oncology

CIDP: Riliprubart Treatment Study

We are studying the long-term safety and effectiveness of riliprubart for individuals with chronic inflammatory demyelinating polyneuropathy. This trial will help us understand how well it works in improving disability and strength.

Chronic Inflammatory Demyelinating Polyneuropathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementNeurology

Budesonide for Inflammation in Functional Dyspepsia

We are studying whether Budesonide can help reduce inflammation and improve symptoms in patients with functional dyspepsia. This trial will also look at its effects on quality of life and emotional well-being.

Functional Dyspepsia3-6 monthsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementGastroenterology

Mucopolysaccharidosis Type IIIA: JR-441 Infusions

We are evaluating the safety and potential effectiveness of JR-441 infusions for patients with mucopolysaccharidosis type IIIA. This study aims to explore how well this treatment works for this rare condition.

Mucopolysaccharidosis III>2 yearsSafety phase (I)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyInternal MedicinePediatrics

Brain Injury and Concussion: Tau Tracer Study

We are investigating whether tau levels in the brain are higher in patients with brain injuries and athletes with concussion symptoms. The study also looks at how these brain levels relate to tau found in blood samples.

Cerebral ConcussionIntracerebral HemorrhageTraumatic Brain Injury>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineNeurology

Golcadomide for Brain Lymphoma: A Phase 2 Study

We are studying the effectiveness of golcadomide in patients with relapsed or refractory large B-cell lymphoma in the brain. The goal is to see if it can help achieve remission and improve overall health.

Diffuse Large B-Cell LymphomaSecondary Central Nervous System LymphomaRelapsed Primary Large B-Cell Lymphoma of the Central Nervous System1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurologyOncology

Cutaneous Melanoma: IMA203 Treatment Study

We are comparing a new treatment called IMA203 with the best available options for patients with advanced skin cancer. This study aims to see if IMA203 is more effective and safe for those who have already been treated.

Skin Melanoma1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Cervical Dystonia: Botulinum Toxin for Back Muscle Activity

We are studying abnormal muscle activity in the back of people with cervical dystonia. The trial will test whether botulinum toxin injections can help improve this condition and what side effects may occur.

Cervical Dystonia>2 yearsMonitoring phase (IV)Standard MedicinesCost ReimbursementInternal MedicineNeurology